The role of emotion in early learning

The lessons of noninterventional and interventional prospective studies on the development of atopic disease during childhood.

Intravenous (i.v.) paracetamol (acetaminophen) is gaining increasing use in neonates (1–3), despite an off-label status in some countries. Product information for i.v. paracetamol does not consider the clearance maturation with age in neonates in its dosing recommendations. In Australasia the same dose of 15 mgAEkg 6 h is suggested for neonates over 10 days of age and for infants and children up to 33 kg. A reduced dose of 7.5 mgAEkg 6 h is proposed in term neonates <10 days of age. In Europe there is no labeled use for neonates <10 days of age. The registered dose is 7.5 mgAEkg 6 h for neonates after 10 days of age through to infants of 10 kg. A dose of 15 mgAEkg 6 h (max daily dose 60 mgAEkg) is recommended between 10 and 40 kg. These dosing regimens suggest something magic about 10 days. There are data concerning the pharmacokinetics of this formulation in neonates. Population pharmacokinetics of the i.v. prodrug (propacetamol) have been studied in neonates following single (4,5) and repeat dose administration (6). Parameter estimates from neonates given repeat doses of i.v. paracetamol over a median of 4 days duration are consistent with those estimated using propacetamol (7). Dosing regimens used in some institutions for neonates have been published in Pediatric Anesthesia (2,8), but there are few data validating the safety or effectiveness of these regimens. The idea that a target effect and associated target concentration can be used to make rational individual dose decisions has acceptance (9). A knowledge of neonatal pharmacokinetics assists with dose prediction to achieve the target concentration. There are, however, flaws and constraints of current knowledge that limit implementation of this approach to dosing.

Brain Mechanisms in Early Language Acquisition

Community-acquired diarrhoea in a world with rotavirus vaccine: a glimpse into the future.

The influence of hyperbilirubinaemia on the infants' cries and the feasibility of the use of cry analysis for the early identification of developing kernicterus were studied by analyzing the cries of 100 healthy one-day-old infants and 31 infants with Rh haemolytic disease of the newborn (Rh-HDN) by using sound spectrographic methods. The newborn infants with Rh-HDN were divided into three subgroups according to the findings in a neurological examination: an evident group (10 infants), a transient group (13 infants) and an asymptomatic group (8 infants) and followed up until one year of age. Cry recording and a neurological examination were carried out once for each of the healthy one-day-old infants and twice a day during the first week of life for the infants with Rh-HDN, and thereafter once a day until discharged and at the ages of 1 and 3 months. Additional neurological examinations were performed on the Rh-HDN infants at the ages of 6 and 12 months. Bilirubin determination was carried out in connection with the cry recordings during the first week of life. The effect of blood exchange transfusion on the cry sound was investigated in infants with a bilirubin level above 250 mumol/l (n = 12) and below this level (n = 15) before the procedure. An electroencephalography (EEG) was recorded once during the neonatal period and once during the follow-up. The cries of the healthy infants were used to develop a cry score comprising 16 characteristics (latency, duration of phonation, maximum and minimum pitch of fundamental frequency, occurrence and maximum pitch of shift, glide, melody form, biphonation, furcation, noise concentration, voice quality, double harmonic break, glottal plosives, vibrato and glottal roll), which was then applied to the analysis of the cries of the 31 infants with Rh-HDN. In addition, maximum pitch of fundamental frequency, furcation and combination of biphonation and/or furcation were studied. The cry score and maximum pitch of fundamental frequency increased most obviously in the infants in the evident group as compared with the values after birth in the various subgroups and with the values of the healthy one-day-old infants or the infants in the asymptomatic group day by day. Both parameters also increased in the asymptomatic group between days 2 and 3 as compared with the initial value after birth and with the healthy infants.(ABSTRACT TRUNCATED AT 400 WORDS)

The management of hypotension in the neonatal intensive care unit

Eyes Open, Ears On: Supporting Hearing Technology Use in Children with Hearing Loss

Article Figures and data Abstract Editor's evaluation Introduction Materials and methods Results Discussion Data availability References Decision letter Author response Article and author information Metrics Abstract Background: The risk of adult onset cardiovascular and metabolic (cardiometabolic) disease accrues from early life. Infection is ubiquitous in infancy and induces inflammation, a key cardiometabolic risk factor, but the relationship between infection, inflammation, and metabolic profiles in early childhood remains unexplored. We investigated relationships between infection and plasma metabolomic and lipidomic profiles at age 6 and 12 months, and mediation of these associations by inflammation. Methods: Matched infection, metabolomics, and lipidomics data were generated from 555 infants in a pre-birth longitudinal cohort. Infection data from birth to 12 months were parent-reported (total infections at age 1, 3, 6, 9, and 12 months), inflammation markers (high-sensitivity C-reactive protein [hsCRP]; glycoprotein acetyls [GlycA]) were quantified at 12 months. Metabolic profiles were 12-month plasma nuclear magnetic resonance metabolomics (228 metabolites) and liquid chromatography/mass spectrometry lipidomics (776 lipids). Associations were evaluated with multivariable linear regression models. In secondary analyses, corresponding inflammation and metabolic data from birth (serum) and 6-month (plasma) time points were used. Results: At 12 months, more frequent infant infections were associated with adverse metabolomic (elevated inflammation markers, triglycerides and phenylalanine, and lower high-density lipoprotein [HDL] cholesterol and apolipoprotein A1) and lipidomic profiles (elevated phosphatidylethanolamines and lower trihexosylceramides, dehydrocholesteryl esters, and plasmalogens). Similar, more marked, profiles were observed with higher GlycA, but not hsCRP. GlycA mediated a substantial proportion of the relationship between infection and metabolome/lipidome, with hsCRP generally mediating a lower proportion. Analogous relationships were observed between infection and 6-month inflammation, HDL cholesterol, and apolipoprotein A1. Conclusions: Infants with a greater infection burden in the first year of life had proinflammatory and proatherogenic plasma metabolomic/lipidomic profiles at 12 months of age that in adults are indicative of heightened risk of cardiovascular disease, obesity, and type 2 diabetes. These findings suggest potentially modifiable pathways linking early life infection and inflammation with subsequent cardiometabolic risk. Funding: The establishment work and infrastructure for the BIS was provided by the Murdoch Children's Research Institute (MCRI), Deakin University, and Barwon Health. Subsequent funding was secured from National Health and Medical Research Council of Australia (NHMRC), The Shepherd Foundation, The Jack Brockhoff Foundation, the Scobie & Claire McKinnon Trust, the Shane O'Brien Memorial Asthma Foundation, the Our Women's Our Children's Fund Raising Committee Barwon Health, the Rotary Club of Geelong, the Minderoo Foundation, the Ilhan Food Allergy Foundation, GMHBA, Vanguard Investments Australia Ltd, and the Percy Baxter Charitable Trust, Perpetual Trustees. In-kind support was provided by the Cotton On Foundation and CreativeForce. The study sponsors were not involved in the collection, analysis, and interpretation of data; writing of the report; or the decision to submit the report for publication. Research at MCRI is supported by the Victorian Government's Operational Infrastructure Support Program. This work was also supported by NHMRC Senior Research Fellowships to ALP (1008396); DB (1064629); and RS (1045161) , NHMRC Investigator Grants to ALP (1110200) and DB (1175744), NHMRC-A*STAR project grant (1149047). TM is supported by an MCRI ECR Fellowship. SB is supported by the Dutch Research Council (452173113). Editor's evaluation This paper provides data from a population-based cohort study on early life infection and proinflammatory, atherogenic metabolomic and lipidomic profiles at 12 months of age. The authors generated matched infection, metabolomics and lipidomics data from 555 infants in a pre-birth longitudinal cohort and they showed that frequent infant infections are associated with adverse metabolomic and lipidomic profiles. They also report that similar profiles are noted with higher glycoprotein acetyls (GlycA), but not hsCRP. The paper is interesting and assesses the role of infection and markers of inflammation on lipid and metabolic profile of patients. It provides a comprehensive analysis of lipids and metabolites in infants in response to infection. https://doi.org/10.7554/eLife.75170.sa0 Decision letter Reviews on Sciety eLife's review process Introduction Infectious diseases are ubiquitous in infancy and childhood, with potential long-term impacts on health across the life course. Infection has been recognised as a potential contributor to atherosclerotic cardiovascular disease (CVD), one of the leading causes of adult morbidity and mortality, since the 19th century (Nieto, 1998). More recent adult studies link previous infection with long-term risks of disease (Bergh et al., 2017; Cowan et al., 2018; Wang et al., 2017). The mechanisms are largely unknown, but likely include immune activation and heightened inflammation (Shah, 2019), which are pathways central to CVD pathogenesis (Donath et al., 2019b; Ferrucci and Fabbri, 2018) and therefore offer potentially druggable targets in high-risk individuals (Donath et al., 2019a; Ridker et al., 2017). High-sensitivity C-reactive protein (hsCRP) has been extensively used as a marker of chronic inflammation in adult studies but is an acute phase reactant in children and may not reflect chronic inflammation in early life. Glycoprotein acetyls (GlycA) is a nuclear magnetic resonance (NMR) composite measure that is suggested to better reflect cumulative, chronic inflammation (Connelly et al., 2017). GlycA is an emerging biomarker for cardiometabolic risk (Connelly et al., 2017) that outperforms hsCRP as a predictor of CVD events and mortality (Akinkuolie et al., 2014; Duprez et al., 2016), and of infection-related morbidity and mortality (Ritchie et al., 2015). For example, in the Multi-Ethnic Study of Atherosclerosis (n = 6523), higher GlycA was associated with increased risk of incidence CVD and death, even after adjustment for hsCRP and other inflammatory markers. Conversely, prediction of these outcomes by hsCRP attenuated to null after mutual adjustment (Duprez et al., 2016). Cardiovascular and metabolic (cardiometabolic) disease pathogenesis begins in early life and accrues across the life course (Nakashima et al., 2008). Infections occur disproportionally in early childhood (Cromer et al., 2014; Grüber et al., 2008; Troeger et al., 2018; Tsagarakis et al., 2018), and there is a dose-response relationship between childhood infections, adverse cardiometabolic phenotypes (Burgner et al., 2015c), and CVD events (Burgner et al., 2015a) in adulthood. Infection is linked to proatherogenic metabolic perturbations in later childhood and adulthood (Feingold and Grunfeld, 2019; Khovidhunkit et al., 2000), including higher triglycerides and oxidised low-density lipoprotein (LDL), and lower high-density lipoprotein (HDL) cholesterol and apolipoprotein A1 (ApoA1) (Liuba et al., 2003; Pesonen et al., 1993), and to acute and chronic inflammation (Burgner et al., 2015b; Ritchie et al., 2015), but little is known about these relationships in early life, when most infections occur. We therefore aimed to characterise metabolomic and lipidomic profiles at 6 and 12 months of age and their relationship to infection burden during the first year of life. We also investigated the extent to which inflammation mediated the relationship between infection burden and metabolomic and lipidomic differences. Materials and methods Study cohort Request a detailed protocol This study used available data from 555 mother-infant dyads in the Barwon Infant Study (BIS), a population-based pre-birth longitudinal cohort (n = 1074 mother-infant dyads). The cohort details and inclusion/exclusion criteria have been detailed elsewhere (Vuillermin et al., 2015); in brief, mothers were eligible if they were residents of the Barwon region in south-east Australia and planned to give birth at the local public or private hospital. Mothers were recruited at approximately 15 weeks' gestation and provided informed consent. They were excluded if they were not a permanent Australian resident, aged <18 years, required an interpreter to complete questionnaires, or had previously participated in BIS. Infants were excluded if they were very preterm (<32 completed weeks gestation) or had a serious illness or major congenital malformation identified during the first few days of life. Ethics approval was granted by the Barwon Health Human Research Ethics Committee (HREC 10/24). Parent-reported infections Request a detailed protocol At the 4-week, 3-month, 6-month, 9-month, and 12-month time points following birth, mothers were asked to report each episode of infant illness or infection since the previous time point using standardised online questionnaires. The number of parent-reported infections from birth to 12 months was defined as the total number of respiratory tract infections, gastroenteritis, conjunctivitis, and acute otitis media episodes. In secondary analyses, numbers of parent-reported infections from birth to 6 months and from 6 to 12 months were considered. It was not possible to identify the proportion of parent-reported infections that lead to health service utilisation (Rowland et al., 2021). Other maternal and infant measures Request a detailed protocol Questionnaires during pregnancy and at birth were used to collect self-reported data on maternal age, household income, maternal education, and prenatal smoking (considered here as a dichotomous any/none exposure). Residential postcode was used to determine neighbourhood disadvantage using the Index of Relative Socio-Economic Disadvantage (IRSD) from the 2011 Socio-Economic Indexes for Areas (SEIFA) (Pink, 2013), with a lower score corresponding to greater socioeconomic disadvantage. Pre-eclampsia (based on International Association of Diabetes and Pregnancy Study Groups criteria; Tranquilli et al., 2014) and gestational diabetes (based on International Society for the Study of Hypertension in Pregnancy criteria; Nankervis et al., 2013) diagnoses were extracted from hospital records. Infant gestational age, birth weight, and mode of delivery (categorised as vaginal, planned caesarean section, or unplanned caesarean section delivery) were collected from birth records, and the age- and sex-standardised birth weight z-score was calculated using the 2009 revised British United Kingdom World Health Organisation (UK-WHO) growth charts (Cole et al., 2011). Postnatal smoking data was collected from questionnaire data, with mothers asked the average number of hours each day someone smoked near or in the same room as the child (Gray et al., 2019). This was dichotomised as any postnatal smoke exposure if >0 hr reported at any time point up to 12 months of age, or no postnatal smoke exposure. Breastfeeding duration up to 12 months of age was collected from maternal questionnaire data. As most evidence for the protective effect of breastfeeding on early life infection is from comparisons between any breastfeeding and no breastfeeding (Victora et al., 2016), and in light of previous evidence in BIS for an association between even a short duration of breastfeeding and lower odds of infection in early infancy (Rowland et al., 2021), we first looked at breastfeeding as a binary (any/none) measure in models (presented in the main text). As most infants (98.2%) were breastfed to some extent, and it is unknown the degree to which breastfeeding, and the timing of breastfeeding, might affect infant metabolomics and lipidomics, we also considered duration of breastfeeding as a continuous variable for sensitivity analyses. Metabolomic and lipidomic profiling Request a detailed protocol Venous peripheral blood was collected from infants at the 6- and 12-month time points in sodium heparin and generally processed within 4 hr, with a minority (197 of 555) of 12-month samples processed after 4 hr (median time for those 197 samples = 19.9 hr, inter-quartile range [IQR] [18.7, 21.4]). The time interval between collection and post-processing storage of samples was included as a covariate in analyses. Due to the bimodal distribution of 12-month sample collection times as samples were either processed same day of collection or the following day, sensitivity analysis excluding participants with a plasma storage time greater than 4 hr (197 out of 555 infants, predominantly processed the following day) was performed, as described in the Statistical analysis section below. Plasma was stored at –80°C, and aliquots were shipped on dry ice to Nightingale Health (Helsinki, Finland) for NMR metabolomic quantification and Baker IDI (Melbourne, Australia) for liquid chromatography/mass spectrometry (LC/MS) lipidomic quantification, as described below. For secondary analyses investigating possible 'reverse causality', that is, whether metabolomic or lipidomic profile at birth was associated with number of parent-reported infections from birth to 6 months of age, metabolomics and lipidomics data using the same platforms from venous cord blood collected at birth, as previously described (Burugupalli et al., 2022; Mansell et al., 2021), was used. The NMR-based metabolomics platform has been described in detail (Kettunen et al., 2016; Soininen et al., 2015), and quantified a broad range of metabolic measures including lipoprotein size subclasses, triglycerides, cholesterols, fatty acids, amino acids, ketone bodies, glycolysis metabolites, and GlycA. In brief, plasma samples were mixed with a sodium phosphate buffer prior to NMR measurements with Bruker AVANCE III 500 MHz and Bruker AVANCE III HD 600 MHz spectrometers (Bruker, Billerica, MA). Samples were kept at 6°C using the SampleJet sample changer (Bruker) to prevent degradation. After initial measurements, samples went through a multiple-step lipid extraction procedure using saturated sodium chloride solution, methanol, dichloromethane, and deuterochloroform. The lipid extracts were then analysed using the 600 MHz instrument (Soininen et al., 2015). The utility of this platform in epidemiological research has been detailed elsewhere (Würtz et al., 2017). Using the Nightingale Health 2016 bioinformatics protocol, 228 metabolomic measures were generated for the 12-month samples. From a subset of participants, replicate samples were quantified, and these showed a low percentage coefficient of variation (<10%). Subsequently, the Nightingale Health 2020 bioinformatics protocol was used to generate 250 metabolomic measures for the 6-month samples, with 224 of these measures also present in the 12-month data. As a large proportion of the NMR metabolomic measures are ratios and are strongly correlated with each other in children and adults (Ellul et al., 2019), an informative subset of 51 measures that captured the majority of variation in the metabolomic dataset, primarily absolute metabolite concentrations, were included in analysis presented in the main text. Analyses for excluded metabolomic measures are presented as supplementary data. To complement GlycA as a measure of inflammation, hsCRP was also quantified in 6- and 12-month plasma using enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN, cat. no. DY1707), as per the manufacturer's instruction. The details of the high-performance LC/MS lipidomics platform have been described elsewhere (Beyene et al., 2020). In addition, we used medronic acid to passivate the LC/MS system to avoid peak tailing for acidic phospholipids (Hsiao et al., 2018). In brief, this platform quantified 776 lipid features in 36 lipid classes, including sphingolipids, glycerophospholipids, sterols, glycerolipids, and fatty acyls. Analysis was performed on an Agilent 6490 QQQ mass spectrometer with an Agilent 1290 series high-performance liquid chromatography system and two ZORBAX eclipse plus C18 column (2.1 × 100 mm 1.8 mm) (Agilent, Santa Clara, CA) with the thermostat set at 45°C. Mass spectrometry analysis was performed in both positive and negative ion mode with dynamic scheduled multiple reaction monitoring. Quantification of lipid species was determined by comparison to the relevant internal standard. Lipid class total concentrations were calculated as the sum of individual lipid species concentrations, except in the case of triacylglycerols (TGs) and alkyl-diacylglycerols, where we measured both neutral loss and single ion monitoring (SIM) peaks, and subsequently used the SIM species concentrations for summation purposes. Statistical analysis Request a detailed protocol Analyses were performed in R (version 3.6.3) (R Development Core Team, 2018). All metabolomic and lipidomic measures had their lowest observed non-zero value (considered the lower limit of detection) added to their value before they were natural log-transformed and scaled to a standard distribution (standard deviation units). Pearson's correlations were calculated for number of infections from birth to 12 months with 12-month GlycA and hsCRP. The estimated effect of number of parent-reported infections from birth to 12 months as an exposure on 12-month metabolomic and lipidomic profile was investigated using linear regression models for each metabolomic/lipidomic measure. Standard errors were used to calculate 95% confidence intervals for estimated effects. All models were adjusted for infant sex, exact age at 12-month time point, birth weight z-score, gestational age, maternal household income, exposure to maternal smoking during pregnancy, breastfeeding, and time from collection to storage for the plasma sample. Linear regression models adjusted for the same covariates were used to investigate 12-month GlycA and hsCRP as exposures and each metabolomic/lipidomic measure as an outcome. Two-tailed p-values were adjusted for multiple comparisons within each dataset (NMR metabolomics, LC/MS lipidomic species, and LC/MS lipidomic classes) using the Benjamini-Hochberg method (Benjamini and Hochberg, 1995). To investigate the robustness of the estimates, mean model coefficients and bias-corrected accelerated percentile bootstrap confidence intervals were calculated from nonparametric bootstrap resampling (1000 iterations) using the 'boot' package (Davison and Hinkley, 1997) (version 1.3–25) in R, included in Source Data. The assumption of linearity was investigated post hoc using plots of residual values for the top 10 metabolomic and lipidomic differences (ranked by p-value) for each of number of infections, GlycA, and hsCRP. To further investigate the other sources of potential confounding and variation that could affect findings from the primary models, several sensitivity analyses were performed. These were: (i) additional adjustment of the primary model for postnatal smoking exposure, gestational diabetes, and pre-eclampsia; (ii) analyses excluding twins (five infants); (iii) analyses excluding infants with hsCRP >5 mg/L (24 infants) as a marker of acute infection (Lemiengre et al., 2018; et al., analyses excluding plasma samples with hr from collection to storage (197 and analyses for breastfeeding duration of any Analyses of the primary models adjusted for measures of socioeconomic or maternal of household were also considered. These models are presented as supplementary plots analyses to investigate 6-month of infections were performed. The birth to 6-month models investigated the relationship between infections up to 6 months of age, 6-month inflammation, and 6-month metabolomic/lipidomic The 6- to 12-month models investigated the relationship of infections between 6 and 12 months of age, 12-month inflammation, and 12-month metabolomic/lipidomic with adjustment for the corresponding 6-month For secondary analyses to investigate regression models et al., were either for (i) each metabolomic/lipidomic measure from cord blood at birth as exposure and total number of infections from birth to 6 months of age as or (ii) each 6-month metabolomic/lipidomic measures as exposure and total number of infections from 6 to 12 months of age as the with adjustment for number of infections from birth to 6 months of age. All secondary models were adjusted for the same covariates as the primary models described that is, infant sex, gestational age, exact age 6- or 12-month time birth weight z-score, maternal household income, exposure to maternal smoking during pregnancy, and sample time between collection and post-processing with birth metabolomic/lipidomic measures as the exposure were adjusted for mode of which is associated with differences across NMR metabolomic measures in cord in this cohort et al., 2021). To investigate the potential role of inflammation in mediating associations between infection and metabolic the package et al., 2017) (version in R was then used in a to the natural effect mediated by and natural effect by of infection. 12-month GlycA or hsCRP were considered as for the effect of number of infections from birth to 12 months of age on metabolomic and lipidomic differences at 12 months, for metabolomic and lipidomic measures associated with number of infections with an adjusted from the linear regression models described mediation was calculated as the estimated natural effect by the total effect effect plus natural of the mediation model is in for model investigated in this The natural effect by glycoprotein acetyls or C-reactive protein and natural effect mediated by of parent-reported infections on metabolomic and lipidomic measures were with adjustment for were considered to for associations to exposure to and to As models investigating described suggested that 6-month GlycA or lipidomic measures may number of infections from 6 to 12 months of age, we performed mediation analyses to the percentage mediation of 12-month GlycA and hsCRP for the effect of number of infections from 6 to 12 months of age on 12-month metabolomic and lipidomic with additional adjustment for the corresponding 6-month measures of infections from birth to 6 months of age, 6-month GlycA or and the 6-month metabolomic/lipidomic Results The for the 555 infants included in this study is in and the cohort for these infants are in The number of total parent-reported infections from birth to 12 months of age was = infections from birth to 6 months of age was 2 and infections from 6 to 12 months of age was 12-month hsCRP and GlycA were mg/L and number of parent-reported infections between birth and 12 months of age was more strongly correlated with 12-month GlycA = than hsCRP = The of metabolomic and lipidomic measures at each time point for the cohort are in and (n = age at delivery smoking during pregnancy diabetes (n = (n = household to to to to (n = than year 10 of 10 of or 12 of or of birth caesarean caesarean postnatal smoke exposure to 12 months (n = of duration to weeks age weight weight at 6-month time point at 6 months z-score at 6 at 12-month time point at 12 months z-score at 12 of parent-reported infections from birth to 12 Infections from birth to 6 Infection from 6 to 12 GlycA at 6 months at 6 months at 12 months at 12 months All = 555 infants had complete covariate data for primary models, data of secondary exposures is to the relevant measure. lower value greater socioeconomic disadvantage on 2 of Barwon Infant Study participants included this study participants had complete infection data from time points between birth and 12 months of age, and 12-month plasma nuclear magnetic resonance (NMR) metabolomics data. included participants (n = out of 555) had 12-month plasma liquid chromatography/mass spectrometry (LC/MS) lipidomics data. Infection and inflammation burden and plasma NMR metabolomic profile at 12 months was evidence for higher number of infections with higher inflammatory markers per infection, 95% and hsCRP lower HDL to to and to cholesterols, lower to lower to higher and to a extent with higher triglycerides and lower to In models with GlycA as the marker of inflammation metabolomic differences observed for higher GlycA were largely similar but more those for parent-reported including HDL per in GlycA to higher and lipoprotein to higher apolipoprotein higher total fatty higher total triglycerides and amino and lower to metabolites lower to and lower to were generally similar to standard regression for models. effect were generally similar across most sensitivity analyses excluding samples with time greater than 4 hr the of estimated of parent-reported infections on HDL and hsCRP was associated with lower HDL cholesterol per in to to and to and higher to as observed for GlycA, and with lower of most other amino and to and higher triglycerides with 2 in 12-month plasma nuclear magnetic resonance (NMR) metabolomic measures for each in parent-reported infection to 12 and for each in 12-month glycoprotein acetyls (GlycA) (n = plots of the estimated 12-month metabolomic differences for each additional parent-reported infection from birth to 12 months or 12-month GlycA from adjusted linear regression models, and the

What should we tell allergic families about pets?

Infant acetaminophen use associates with early asthmatic symptoms independently of respiratory tract infections: The Copenhagen Prospective Study on Asthma in Childhood 2000 (COPSAC2000) cohort

Nutrition and maternal, neonatal, and child health

Presentation, clinical course, and outcome of childhood stroke

Chapter 11 Man in Extreme Environments, Problems of the Newborn and Elderly

Nonfatal Isolated Cardiac Nonlysosomal Glycogenosis: A Rare Cause of Infantile Hypertrophic Cardiomyopathy

Craniosynostosis is a condition in which 1 or more cranial sutures fuse prematurely, often secondary to a fibroblast growth factor receptor (FGFR) mutation, typically involving FGFR2 or FGFR3. This mutation may occur sporadically or in the setting of a genetic syndrome and typically presents within the first few days of life or in early infancy. Most commonly, the sagittal and coronal sutures are involved, although involvement of the lambdoidal and/or metopic sutures is not uncommon. Surgical correction is undertaken both for cosmetic purposes and to relieve raised intracranial pressure, both of which can be severe, depending on the sutures involved. We report on 2 children who presented in their first year of life with synostosis involving: in one instance, a single squamous temporal suture, and in the other, both squamous temporal sutures. The initial presentation and clinical courses of these 2 patients are highly distinct from one another, although both ultimately did quite well after extensive cranial remodeling. To the best of our knowledge, only a handful of patients with squamous synostosis have been reported in the medical literature.